Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Radiation Oncology|
Surgery
Advertisement

Philip Blumenfeld, MD

Advertisement

Articles by Philip Blumenfeld, MD

Philip Blumenfeld, MD, reviewed efficacy signals from a pooled analysis of Alpha DaRT in pancreatic cancer.

Alpha DaRT Elicits 100% Local Disease Control in Pancreatic Cancer

ByPhilip Blumenfeld, MD
May 21st 2026

Philip Blumenfeld, MD, reviewed efficacy signals from a pooled analysis of Alpha DaRT in pancreatic cancer.

Philip Blumenfeld, MD, discussed the biological rationale and distinct mechanism of action of EUS-guided radium-224 Alpha DaRT in pancreatic adenocarcinoma.

Alpha DaRT Overcomes Anatomical Constraints in Inoperable Pancreatic Cancer

ByPhilip Blumenfeld, MD
May 20th 2026

Philip Blumenfeld, MD, discussed the biological rationale and distinct mechanism of action of EUS-guided radium 224 Alpha DaRT in pancreatic adenocarcinoma.

Advertisement

Latest Updated Articles

  • Philip Blumenfeld, MD, discussed the biological rationale and distinct mechanism of action of EUS-guided radium-224 Alpha DaRT in pancreatic adenocarcinoma.
    Alpha DaRT Overcomes Anatomical Constraints in Inoperable Pancreatic Cancer

    May 20th 2026



Advertisement
Advertisement

Trending on CancerNetwork

1

GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence

2

84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study

3

FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer

4

BCMA CAR T-Cell Therapy Improves OS Vs Teclistamab in Multiple Myeloma

5

Radiation Oncology Trials You May Have Missed at ASCO 2026

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us